Skip to main content
Skip to main content
PRVL logo

PRVL Stock Analysis

PRVL bottom line: signals are mixed — the Council read leans Bearish Lean (32/100) while the AI fundamental score is 50/100 (grade B); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Ray Dalio bullish.
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

PRVL — AI-powered stock analysis, MoonshotScore 50/100.

Last analyzed: Aug 18, 2026
Watch the PRVL film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Bearish Lean 32/100 · D

PRVL: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PRVL Company Overview

Data Provenance | Financial Data Quantitative Analysis

Who Are PRVL's Competitors?

PRVL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
VRTX Vertex Pharmaceuticals Incorporated $540.26 -2.14% $137B 98
REGN Regeneron Pharmaceuticals, Inc. $835.15 -0.68% $86.0B 94
ALNY Alnylam Pharmaceuticals, Inc. $229.30 -5.49% $30.7B 92
RPRX Royalty Pharma plc $60.58 -1.86% $26.9B 75
INCY Incyte Corporation $127.80 -0.53% $25.9B 99
UTHR United Therapeutics Corporation $520.23 -1.68% $22.1B 98
NBIX Neurocrine Biosciences, Inc. $153.42 -1.37% $15.4B 93
EXEL Exelixis, Inc. $53.69 -1.29% $13.5B 98

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are the Key Risks for PRVL?

Negative return on equity (-38.2%) — the business is not currently generating profit on shareholder capital.

How PRVL Is Valued

Relative to its peer group, PRVL's quantitative score of 50/100 is below the peer average of 92/100.

ROE -38%

Key Financial Metrics

Return on equity for PRVL stands at -38.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.8%, showing how much profit it generates from its asset base. A current ratio of 14.74 indicates the company holds enough short-term assets to cover its near-term obligations.

PRVL Financials

Fundamental Snapshot

Return on Equity (TTM)
-38.2%
Current Ratio
14.7

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in PRVL's future, indicating that those closest to the company believe in its potential.
  • Social sentiment has turned positive, with discussions highlighting innovative product developments that could drive growth.
  • Analysts have noted a favorable market position, with PRVL addressing a niche that is gaining traction among consumers.
  • Community sentiment reflects optimism about upcoming partnerships that may enhance market visibility and credibility.

Bear Case

  • Concerns have emerged regarding the sustainability of recent growth, with some analysts questioning the long-term viability of PRVL's business model.
  • Social media sentiment has shown mixed feelings, with some users expressing skepticism about the company's ability to scale operations effectively.
  • Recent earnings reports did not meet expectations, leading to a cautious outlook from parts of the investor community.
  • Increased competition in PRVL's sector has raised alarms about potential market share erosion, prompting bearish discussions among traders.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

PRVL Latest News

No recent news available for PRVL.

PRVL Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PRVL.

Price Targets

Wall Street price target analysis for PRVL.

PRVL MoonshotScore

50/100

What does this score mean?

The MoonshotScore rates PRVL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Common Questions About PRVL

What does the AI Score mean for PRVL?

PRVL holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. PRVL AI Score: 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation.

What are the key factors to evaluate for PRVL?

Evaluate PRVL on fundamentals, analyst consensus, and risk factors. Not financial advice.

How frequently does PRVL data refresh on this page?

PRVL prices refresh on page view and on a rolling daily schedule; the last-updated date appears near the top of this page. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven PRVL's recent stock price performance?

PRVL moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PRVL overvalued or undervalued right now?

PRVL has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research PRVL before investing?

Before investing in PRVL, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding PRVL to a portfolio?

No dossier-level strength is on record for PRVL yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.

Can I buy fractional shares of PRVL?

Yes, most major brokerages offer fractional shares of PRVL with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track PRVL's earnings and financial reports?

PRVL reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for PRVL earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Popular Stocks

More Stocks We Cover